Logo image of ANIP

ANI PHARMACEUTICALS INC (ANIP) Stock Fundamental Analysis

NASDAQ:ANIP - Nasdaq - US00182C1036 - Common Stock - Currency: USD

62.12  -0.66 (-1.05%)

After market: 62.12 0 (0%)

Fundamental Rating

5

Overall ANIP gets a fundamental rating of 5 out of 10. We evaluated ANIP against 195 industry peers in the Pharmaceuticals industry. ANIP has only an average score on both its financial health and profitability. An interesting combination arises when we look at growth and value: ANIP is growing strongly while it also seems undervalued.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year ANIP was profitable.
In the past year ANIP had a positive cash flow from operations.
ANIP had negative earnings in 4 of the past 5 years.
ANIP had a positive operating cash flow in 4 of the past 5 years.
ANIP Yearly Net Income VS EBIT VS OCF VS FCFANIP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

1.2 Ratios

Looking at the Return On Assets, with a value of -0.50%, ANIP belongs to the top of the industry, outperforming 80.51% of the companies in the same industry.
ANIP has a better Return On Equity (-1.45%) than 82.05% of its industry peers.
ANIP has a Return On Invested Capital of 2.10%. This is in the better half of the industry: ANIP outperforms 78.46% of its industry peers.
Industry RankSector Rank
ROA -0.5%
ROE -1.45%
ROIC 2.1%
ROA(3y)-2.12%
ROA(5y)-3.36%
ROE(3y)-5.31%
ROE(5y)-7.87%
ROIC(3y)N/A
ROIC(5y)N/A
ANIP Yearly ROA, ROE, ROICANIP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 -10

1.3 Margins

Looking at the Operating Margin, with a value of 3.58%, ANIP is in the better half of the industry, outperforming 79.49% of the companies in the same industry.
In the last couple of years the Operating Margin of ANIP has declined.
The Gross Margin of ANIP (60.17%) is better than 68.72% of its industry peers.
ANIP's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 3.58%
PM (TTM) N/A
GM 60.17%
OM growth 3YN/A
OM growth 5Y-47.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.51%
GM growth 5Y-3.12%
ANIP Yearly Profit, Operating, Gross MarginsANIP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

ANIP has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for ANIP has been increased compared to 1 year ago.
The number of shares outstanding for ANIP has been increased compared to 5 years ago.
The debt/assets ratio for ANIP is higher compared to a year ago.
ANIP Yearly Shares OutstandingANIP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ANIP Yearly Total Debt VS Total AssetsANIP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 1.87 indicates that ANIP is not a great score, but indicates only limited risk for bankruptcy at the moment.
ANIP has a better Altman-Z score (1.87) than 66.15% of its industry peers.
ANIP has a debt to FCF ratio of 9.35. This is a negative value and a sign of low solvency as ANIP would need 9.35 years to pay back of all of its debts.
ANIP has a Debt to FCF ratio of 9.35. This is amongst the best in the industry. ANIP outperforms 80.51% of its industry peers.
A Debt/Equity ratio of 1.38 is on the high side and indicates that ANIP has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.38, ANIP is doing worse than 74.87% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.38
Debt/FCF 9.35
Altman-Z 1.87
ROIC/WACC0.22
WACC9.71%
ANIP Yearly LT Debt VS Equity VS FCFANIP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

ANIP has a Current Ratio of 2.66. This indicates that ANIP is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.66, ANIP perfoms like the industry average, outperforming 46.67% of the companies in the same industry.
A Quick Ratio of 1.98 indicates that ANIP should not have too much problems paying its short term obligations.
ANIP has a Quick ratio (1.98) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 1.98
ANIP Yearly Current Assets VS Current LiabilitesANIP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

8

3. Growth

3.1 Past

ANIP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.54%, which is quite good.
ANIP shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 0.59% yearly.
Looking at the last year, ANIP shows a very strong growth in Revenue. The Revenue has grown by 56.85%.
The Revenue has been growing by 24.37% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)19.54%
EPS 3Y16.84%
EPS 5Y0.59%
EPS Q2Q%40.5%
Revenue 1Y (TTM)56.85%
Revenue growth 3Y41.66%
Revenue growth 5Y24.37%
Sales Q2Q%43.43%

3.2 Future

ANIP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.58% yearly.
The Revenue is expected to grow by 10.09% on average over the next years. This is quite good.
EPS Next Y26.64%
EPS Next 2Y17.87%
EPS Next 3Y16.98%
EPS Next 5Y12.58%
Revenue Next Year30.85%
Revenue Next 2Y18.7%
Revenue Next 3Y14.65%
Revenue Next 5Y10.09%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ANIP Yearly Revenue VS EstimatesANIP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
ANIP Yearly EPS VS EstimatesANIP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6 8 10

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 10.92, the valuation of ANIP can be described as reasonable.
Based on the Price/Earnings ratio, ANIP is valued cheaply inside the industry as 90.26% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.60. ANIP is valued rather cheaply when compared to this.
ANIP is valuated reasonably with a Price/Forward Earnings ratio of 8.60.
Based on the Price/Forward Earnings ratio, ANIP is valued cheaper than 86.15% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ANIP to the average of the S&P500 Index (22.39), we can say ANIP is valued rather cheaply.
Industry RankSector Rank
PE 10.92
Fwd PE 8.6
ANIP Price Earnings VS Forward Price EarningsANIP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ANIP is valued cheaper than 80.51% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ANIP is valued cheaply inside the industry as 83.59% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 20.19
EV/EBITDA 17.22
ANIP Per share dataANIP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ANIP's earnings are expected to grow with 16.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.41
PEG (5Y)18.59
EPS Next 2Y17.87%
EPS Next 3Y16.98%

More info and screens

0

5. Dividend

5.1 Amount

ANIP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANI PHARMACEUTICALS INC

NASDAQ:ANIP (6/12/2025, 8:00:01 PM)

After market: 62.12 0 (0%)

62.12

-0.66 (-1.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners95.29%
Inst Owner Change3.51%
Ins Owners6.75%
Ins Owner Change8.06%
Market Cap1.34B
Analysts84.29
Price Target83.93 (35.11%)
Short Float %10.31%
Short Ratio4.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP-25.25%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.96%
Min EPS beat(2)11.36%
Max EPS beat(2)20.55%
EPS beat(4)4
Avg EPS beat(4)14.54%
Min EPS beat(4)5.26%
Max EPS beat(4)20.97%
EPS beat(8)8
Avg EPS beat(8)28.1%
EPS beat(12)11
Avg EPS beat(12)36.05%
EPS beat(16)12
Avg EPS beat(16)13.46%
Revenue beat(2)2
Avg Revenue beat(2)6.75%
Min Revenue beat(2)6.54%
Max Revenue beat(2)6.96%
Revenue beat(4)4
Avg Revenue beat(4)4.78%
Min Revenue beat(4)0.74%
Max Revenue beat(4)6.96%
Revenue beat(8)8
Avg Revenue beat(8)7.86%
Revenue beat(12)12
Avg Revenue beat(12)8.42%
Revenue beat(16)14
Avg Revenue beat(16)6.64%
PT rev (1m)1.05%
PT rev (3m)3.94%
EPS NQ rev (1m)-7.93%
EPS NQ rev (3m)6.5%
EPS NY rev (1m)2.14%
EPS NY rev (3m)16.15%
Revenue NQ rev (1m)-0.42%
Revenue NQ rev (3m)5.73%
Revenue NY rev (1m)1.87%
Revenue NY rev (3m)2.66%
Valuation
Industry RankSector Rank
PE 10.92
Fwd PE 8.6
P/S 1.66
P/FCF 20.19
P/OCF 16.66
P/B 3.03
P/tB N/A
EV/EBITDA 17.22
EPS(TTM)5.69
EY9.16%
EPS(NY)7.22
Fwd EY11.63%
FCF(TTM)3.08
FCFY4.95%
OCF(TTM)3.73
OCFY6%
SpS37.48
BVpS20.48
TBVpS-7.19
PEG (NY)0.41
PEG (5Y)18.59
Profitability
Industry RankSector Rank
ROA -0.5%
ROE -1.45%
ROCE 2.66%
ROIC 2.1%
ROICexc 2.45%
ROICexgc 6.82%
OM 3.58%
PM (TTM) N/A
GM 60.17%
FCFM 8.21%
ROA(3y)-2.12%
ROA(5y)-3.36%
ROE(3y)-5.31%
ROE(5y)-7.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-44.22%
ROICexc growth 3YN/A
ROICexc growth 5Y-46.62%
OM growth 3YN/A
OM growth 5Y-47.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.51%
GM growth 5Y-3.12%
F-Score4
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 1.38
Debt/FCF 9.35
Debt/EBITDA 5.83
Cap/Depr 18.61%
Cap/Sales 1.74%
Interest Coverage 1.15
Cash Conversion 76.92%
Profit Quality N/A
Current Ratio 2.66
Quick Ratio 1.98
Altman-Z 1.87
F-Score4
WACC9.71%
ROIC/WACC0.22
Cap/Depr(3y)17.9%
Cap/Depr(5y)14.57%
Cap/Sales(3y)2.42%
Cap/Sales(5y)2.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.54%
EPS 3Y16.84%
EPS 5Y0.59%
EPS Q2Q%40.5%
EPS Next Y26.64%
EPS Next 2Y17.87%
EPS Next 3Y16.98%
EPS Next 5Y12.58%
Revenue 1Y (TTM)56.85%
Revenue growth 3Y41.66%
Revenue growth 5Y24.37%
Sales Q2Q%43.43%
Revenue Next Year30.85%
Revenue Next 2Y18.7%
Revenue Next 3Y14.65%
Revenue Next 5Y10.09%
EBIT growth 1Y-44.16%
EBIT growth 3YN/A
EBIT growth 5Y-34.31%
EBIT Next Year33.94%
EBIT Next 3Y19.79%
EBIT Next 5Y14.11%
FCF growth 1Y55608.3%
FCF growth 3Y297.63%
FCF growth 5Y4.15%
OCF growth 1Y781.43%
OCF growth 3Y168.16%
OCF growth 5Y7.01%